Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Scott H. Davis who wrote (506)	1/25/2001 6:09:13 PM
From: Scott H. Davis	Respond to of 3557

Regeneron Announces Filing of Registration Statement for Common Stock TARRYTOWN, N.Y.--(BUSINESS WIRE)--Jan. 25, 2001--Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN - news) announced that it filed a registration statement with the Securities and Exchange Commission for a proposed offering by the Company of 4,000,000 shares of the Company's common stock, with an additional 600,000 shares available to cover an over-allotment option. The public offering is being underwritten by Merrill Lynch & Co., JP Morgan, and Robertson Stephens. A registration statement relating to these securities has been filed with Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state. Copies of the prospectus may be obtained from any of the underwriters. Regeneron is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for the treatment of serious medical conditions. Regeneron's platform technologies include Targeted Genomics(TM), Functionomics(TM), and Designer Protein Therapeutics(TM). Regeneron has drugs in clinical trials for the potential treatment of obesity and rheumatoid arthritis, and has preclinical development programs in cancer, asthma, allergies, and other diseases and disorders.